Table 2. All-cause and idiopathic pulmonary fibrosis (IPF)-related mortality in the pooled population
Pirfenidone 2403 mg·day−1#PlaceboHazard ratio (95% CI)+p-value§
Overall
    All-cause mortality27 (8)34 (10)0.77 (0.47–1.28)0.315
    IPF-related mortalityƒ18 (5)28 (8)0.62 (0.35–1.13)0.117
On treatment##
    All-cause mortality19 (6)29 (8)0.65 (0.36–1.16)0.141
    IPF-related mortalityƒ12 (3)25 (7)0.48 (0.24–0.95)0.030

  • Data are presented as n (%), unless otherwise stated. #: n=345; : n=347; +: based on the Cox proportional hazard model; §: log-rank test (pirfenidone versus placebo); ƒ: assessed by the investigator, who remained blinded to treatment assignment; ##: defined as the time from randomisation until 28 days after the last dose of study drug. Reproduced from [38] with permission from the publisher.